CASI PHARMACEUTICALS, INC. Equity Securities, FV-NI, Unrealized Gain (Loss)
CASI PHARMACEUTICALS, INC. (CASIF) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of -$756.00 thousand for the 12-month period ending 2024-12-31, per its 20-F filed 2026-05-15.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2026-05-15
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month |
|---|---|
| 2024-12-31 | -$756.00K 20-F · filed 2026-05-15 |
| 2023-12-31 | -$581.00K 20-F · filed 2024-03-28 |
| 2022-12-31 | -$8.89M 20-F · filed 2024-03-28 |
| 2021-12-31 | $5.66M 20-F · filed 2024-03-28 |
| 2020-12-31 | $4.32M 20-F · filed 2023-04-26 |